News &amp; Updates

Treatment with tirzepatide leads to a reduction in body weight and improvement in glycaemic control in individuals with type 2 diabetes (T2D), reports a study. In addition, it modulates metabolites associated with T2D risk and metabolic dysregulation that is consistent with improved metabolic health.

02 Feb 2022

Effect of interventions on anthropometric outcomes in PCOS varies by drug

In the management of women with polycystic ovary syndrome (PCOS), metformin at various therapeutic doses appears to reduce body weight, body mass index, and waist circumference when compared with placebo, sitagliptin, and acarbose, according to the results of a meta-analysis. On the other hand, pioglitazone and rosiglitazone contribute to an increase in all three outcomes.

Waist circumference, not BMI, a good indicator of outcomes in older diabetics

In older patients with type 2 diabetes (T2D), use of body mass index (BMI) does not adequately predict clinical outcomes associated with obesity, but waist circumference (WC) appears to be up to the task.

02 Feb 2022

High haemoglobin glycation index tied to telomere attrition

A negative association exists between haemoglobin glycation index (HGI) and telomere attrition, independent of HbA1c, according to a study. Tumour necrosis factor (TNF) α mediates the association between HGI and telomere length.

Persistent dysglycaemia dims tuberculosis treatment outcomes

Among patients with tuberculosis (TB) infection, treatment outcomes seem unfavourable in the presence of persistent dysglycaemia, as reported in a study.

Treatment adherence yields QoL gains in congenital adrenal hyperplasia patients

31 Jan 2022

Among teens and adults with congenital adrenal hyperplasia (CAH), adherence to treatment regimens, rather than type of glucocorticoid, is the factor that affects quality of life (QoL), according to a study.

31 Jan 2022

Aflibercept delivers for diabetic macular oedema in real-world study

Real-world data show that aflibercept effectively improves visual acuity (VA) outcomes in patients with diabetic macular oedema. However, factors such as age, baseline VA, and deprivation may affect the effectivity of aflibercept.

Pregnant women with type 1 diabetes likely to have gut inflammation

Women with type 1 diabetes present with a shift in the gut mycobiome across pregnancy, and this shift is strongly linked to gut inflammation and impaired intestinal barrier function, as reported in a study.